Item 8.01. Other Events.

On January 20, 2023, KemPharm, Inc.'s (the "Company") board of directors set the date of the Company's 2023 annual meeting of stockholders (the "2023 Annual Meeting") as April 25, 2023.

Any stockholder seeking to bring business before the 2023 Annual Meeting or to nominate a director for election at the 2023 Annual Meeting pursuant to the Company's Amended and Restated Bylaws (the "Bylaws") must provide timely notice, as set forth in the Bylaws. Specifically, written notice of any proposed business or nomination must be received at the Company's principal executive offices at 1180 Celebration Boulevard, Suite 103, Celebration, FL 34747 no later than January 30, 2023. Stockholders are advised to review the Bylaws, which contain additional requirements about advance notice of stockholder proposals and director nominations.

In addition to satisfying the foregoing requirements under the Bylaws, to comply with the universal proxy rules, stockholders who intend to solicit proxies in support of director nominees other than the Company's nominees must provide notice that sets forth the information required by Rule 14a-19 under the Securities Exchange Act of 1934, as amended (the "Exchange Act").

Stockholders who intend to have a proposal considered for inclusion in the Company's 2023 proxy materials for presentation at its 2023 Annual Meeting pursuant to Rule 14a-8 under the Exchange Act must submit the proposal in writing to the Company's Corporate Secretary by January 30, 2023.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses